Ann: Appendix 4D Half Year Report, page-3

What do you see that is solid about it apart from their balance sheet growing, which seems to be their go to every report. It is a good sign for a company obviously, but it seems to be the same focus point every time. Nice rise in revenue, but cost of materials is up massively and costs of employees. It wasn’t a bad result but I wouldn’t say it was great. No updates on any of the trials or the sixth indication they have been going in about for months and months. Good to see them spending a lot on r&d though. Maybe we might hear some updates this year if we are lucky.